A complex of a chaperone with .beta.-amyloid and methods employing this complex
CA 2348545 C · Owner: Holtzman, Jordan L. · Inventors: Holtzman, Jordan L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A chaperone protein Q2 and ~-amyloid can form a complex. This complex can be detected in a biological sample, such as for example, tissues or fluids from , a mammal. Q2 levels can also be detected in a biological sample. A method for determining the Q2 level in a biological sample and comparing that level to a normal Q2 level can be used to detect, screen diagnose, or otherwise , determine a person's susceptibility to Alzheimer's disease such as for , example, the presence or absence of Alzheimer's disease of symptoms of this , disease, of factors leading to or associated with this disease of likelihood , of developing this disease and the like. In one embodiment, a decline in Q2 level …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 29, 1999 and granted August 21, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 29, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 29, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.